Biography
A trusted intellectual property adviser, Scott counsels clients in the pharmaceutical, chemical, nutraceutical and medical device industries on a variety of legal issues, particularly those involving patents.
Scott's background in molecular and cancer biology, and knowledge of monoclonal antibodies, puts him in an especially strong position to advise life sciences clients on a full range of matters such as:
- Patent prosecution
- Patent term extension and adjustment
- Post-grant proceedings including inter partes reviews and post-grant reviews
- Post-grant reviews
- Opinions (invalidity, clearance, due diligence)
- Litigation, including Hatch-Waxman and Biosimilar (BPCIA) litigation
- Trade secrets
- European oppositions
He has also assisted clients in developing worldwide patent portfolios designed to address generic and biosimilar competition.
Scott has experience with a wide variety of medical technology, including CRISPR, antibody-drug conjugates, exon skipping, AAV vectors, small molecule therapeutics, diagnostics and cell-based therapy.
He represents clients in matters before the U.S. Patent and Trademark Office and in U.K. and European patent actions.
Before Fox Rothschild
Prior to joining Fox Rothschild, Scott was a partner at two international law firms. Before that, he was an associate at a New York-based boutique intellectual property firm.
Before he began his legal career, Scott pursued doctoral studies in cancer biology at Stanford University.
Beyond Fox Rothschild
Scott served as an adjunct professor at the Franklin Pierce Law Center for three years. He was also a faculty member in the biotechnology section of the Practicing Law Institute’s Advanced Patent Prosecution Workshop.
Bar Admissions
- California
- New York
- U.S. Patent & Trademark Office
Education
- Columbia Law School (J.D., 1997)
- Princeton University (B.A., 1986)
Honors & Awards
- Named to The Legal 500 U.S. for Patent Litigation, 2021
